PRESSRELEASE

SHIONOGI

Notice Regarding Relocation of the Tokyo Nihonbashi Office

OSAKA, Japan, September 25, 2026 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that it plans to relocate its Tokyo Nihonbashi Office in or after June 2029 to a building being developed as part of the Tamachi Station West Exit Area Development Project in Minato-ku, Tokyo. The project* is being undertaken by Mitsui Fudosan Co., Ltd., Morinaga Milk Industry Co., Ltd., and East Japan Railway Company.
The office will also be renamed in conjunction with the relocation. Further details will be announced in due course.
* Mitsui Fudosan | Neighborhood Gateway to Undergo RenewalConstruction Begins on Tamachi Station West Exit Area Development Project (October 1, 2025)

1. Overview of the Relocation

- **New location**
  5-412-6 Shiba, Minato-ku, Tokyo 108-0014, Japan (lot number), and other lots

Rendering of the new office building (the station plaza; provided by Mitsui Fudosan Co., Ltd.)

- **Timing of relocation**
  In or after June 2029 (planned)

2. **Background and Purpose of the Relocation**

The Tokyo Nihonbashi Office is one of SHIONOGI Group's key locations, bringing together a wide range of business functions. The relocation is intended to provide an office environment in which an increasingly diverse workforce can work more comfortably and effectively.

In November 2025, Shionogi relocated its Osaka head office and established it as its Global Headquarters under the office concept "FACE," positioning it as "a space that supports an ever-evolving SHIONOGI, where individual employees with pride and aspirations come together to create new value." For the relocation of the Tokyo Nihonbashi Office, Shionogi will likewise develop an office environment and functions befitting the "FACE" concept as SHIONOGI's base in Tokyo.

3. **Features of the New Office**

- **Accelerating Communication**

  While respecting employees' diverse ways of working, Shionogi aims to create an environment that strengthens communication and collaboration both internally and externally, further improves the quality and speed of its business activities, and helps generate new value.

- **Further Enhancing Safety and Security**

  As a HaaS company, Shionogi has a social responsibility to ensure the stable supply of products and services that contribute to the treatment of disease and improvement of quality of life. It is therefore essential to establish systems that enable the continued supply of products and services under any circumstances, including disasters, as well as working arrangements that help enhance employee productivity. The relocated office is expected not only to provide employees with an even safer and more secure workplace, but also to establish the physical and functional resilience needed to maintain business operations in unforeseen circumstances.

Shionogi, which will mark the 150th anniversary of its founding in March 2028, views this relocation as an important step toward accelerating its growth as a company that strives to supply the best possible medicine (healthcare solutions) to protect the health and wellbeing of the patients we serve worldwide. Shionogi will continue striving to contribute to society through the research, production and promotion of ever better medicines and healthcare solutions.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html